Our pipeline comprises genetic medicines strategically developed to target key pathological mechanisms underlying these conditions.

TDP-43 is a key protein implicated in both Amyotrophic Lateral Sclerosis and Frontotemporal Dementia, where its abnormal accumulation and mislocalization contribute to neuronal degeneration and symptom progression.

Building on groundbreaking discoveries, we have pioneered genetic proteolysis targeting chimeras (=genProTAC) to specifically target TDP-43 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia, and halt disease progression.

In Alzheimer’s disease, the progressive accumulation of amyloid-β and tau disrupts synaptic communication and neural circuitry, leading to widespread neuronal network failure that impairs cognitive function and contributes to memory loss and other neurological symptoms.

Through deep understanding of critical disease mechanisms, we have devised a new genetic medicine designed to target tau-dependent neurodegeneration and slow cognitive decline.

In addition to the therapeutic pipeline, the Celosia Therapeutics innovation team develops new tools for accurate diagnosis and precise evaluation of therapeutic efficacy in TDP-43-associated disorders. 

Together, these cutting-edge therapies and diagnostic platforms underscore Celosia Therapeutics’ commitment to transforming treatment for those living with neurodegenerative diseases.